{"hands_on_practices": [{"introduction": "Proving that a medical product caused a specific patient's injury is a critical step in any liability claim. This practice explores the powerful connection between epidemiology and the legal standard of causation. You will learn how to translate a statistical measure, the relative risk ($RR$), into a probability of causation ($PC$), allowing you to determine if the \"preponderance of the evidence\" threshold is met in a hypothetical case. [@problem_id:4496650]", "problem": "A patient experienced an acute adverse event after receiving a prescription medical device-assisted therapy in a hospital setting. The manufacturer of the device provided risk information to the treating physician, but the plaintiff alleges that the warning was inadequate under the learned intermediary doctrine (the legal rule that the manufacturer’s duty to warn runs to the physician rather than directly to the patient). Assume general causation is established by high-quality epidemiological evidence showing that exposure to the device-associated therapy increases the risk of the adverse event. A meta-analysis reports a relative risk of $RR=3.0$ for the adverse event among exposed patients compared to similarly situated unexposed patients.\n\nUnder the civil burden of proof for tort claims, the plaintiff must satisfy the “preponderance of the evidence” standard, meaning it is more likely than not (greater than $0.5$ in probability) that the defendant’s conduct caused the harm. In the legal use of epidemiology for specific causation, the probability of causation for an exposed case can be aligned with the attributable fraction among the exposed when appropriate assumptions hold (including that the reported $RR$ applies to the plaintiff’s exposure circumstances, that confounding is sufficiently controlled, and that no alternative cause better explains the injury).\n\nStarting strictly from the foundational definitions:\n- Relative risk is $RR=\\frac{P(D \\mid E)}{P(D \\mid \\neg E)}$, where $D$ denotes occurrence of the adverse event and $E$ denotes exposure.\n- The attributable fraction among the exposed is the proportion of $P(D \\mid E)$ attributable to exposure rather than baseline risk.\n\nDerive an expression for the probability of causation in terms of $RR$ and then compute its value for $RR=3.0$. Finally, state whether this value meets the civil “more likely than not” threshold, based on the resulting probability. Express the probability of causation as a decimal and round your final numerical answer to four significant figures. No units are required.", "solution": "The legal analysis of specific causation in medical product liability can incorporate epidemiological measures under established assumptions. The probability of causation for an exposed individual case can be represented, under appropriate conditions, by the attributable fraction among the exposed.\n\nBegin with the fundamental definitions. Let $D$ denote the occurrence of the adverse event and $E$ denote exposure. The relative risk is\n$$\nRR=\\frac{P(D \\mid E)}{P(D \\mid \\neg E)}.\n$$\nThe risk difference attributable to exposure among the exposed is\n$$\n\\text{Risk difference among exposed} = P(D \\mid E) - P(D \\mid \\neg E).\n$$\nThe attributable fraction among the exposed (the proportion of the exposed risk attributable to the exposure) is\n$$\n\\text{AFE} = \\frac{P(D \\mid E) - P(D \\mid \\neg E)}{P(D \\mid E)}.\n$$\nSubstitute the definition of $RR$ to rewrite $P(D \\mid \\neg E)$ in terms of $P(D \\mid E)$:\n$$\nP(D \\mid \\neg E) = \\frac{P(D \\mid E)}{RR}.\n$$\nTherefore,\n$$\n\\text{AFE} = \\frac{P(D \\mid E) - \\frac{P(D \\mid E)}{RR}}{P(D \\mid E)} = 1 - \\frac{1}{RR} = \\frac{RR - 1}{RR}.\n$$\nUnder the usual legal-epidemiological alignment (assuming the reported $RR$ applies to the plaintiff’s exposure and injury context, and that confounding and alternative causes are adequately addressed), the probability of causation for an exposed case equals the attributable fraction among the exposed:\n$$\nPC = \\text{AFE} = \\frac{RR - 1}{RR}.\n$$\nNow compute $PC$ for $RR=3.0$:\n$$\nPC = \\frac{3.0 - 1}{3.0} = \\frac{2.0}{3.0} = 0.666\\ldots\n$$\nRounded to four significant figures, this is\n$$\nPC \\approx 0.6667.\n$$\nInterpretation for the civil burden of proof: The “preponderance of the evidence” standard corresponds to a probability greater than $0.5$. Here, $PC=0.6667$ exceeds $0.5$, indicating that, under the stated assumptions, it is more likely than not that the exposure (the device-associated therapy) caused the plaintiff’s adverse event. In the learned intermediary doctrine framework, if the manufacturer’s inadequate warning to the physician is established, this $PC$ supports the element of specific causation by showing that the injury is more likely than not attributable to the exposure; proximate causation would further require evidence that an adequate physician warning would have changed prescribing or monitoring behavior in a way that would have avoided the harm.", "answer": "$$\\boxed{0.6667}$$", "id": "4496650"}, {"introduction": "Once causation is established, a claim often turns on whether the product was defectively designed. This exercise contrasts two primary legal standards for design defect: the intuitive \"consumer-expectation\" test and the more analytical \"risk-utility\" test. By applying these frameworks to a complex, high-risk implantable device, you will see why the existence of a \"feasible alternative design\" is often the central question in modern medical device litigation. [@problem_id:4496680]", "problem": "A patient with ventricular tachycardia received an Implantable Cardioverter-Defibrillator (ICD) lead approved by the Food and Drug Administration (FDA) through premarket approval. The lead uses a thin, high-fatigue-resistance conductor to minimize diameter. The manufacturer’s Instructions for Use (IFU) provided a physician-facing warning that, based on post-market surveillance, the lead carried an approximate conductor-fracture risk of $1$ in $500$ (that is, $0.2\\%$) over the first $3$ years in typical activity levels. The IFU emphasized that early detection of microfracture could be difficult and that fracture could cause inappropriate shocks and revision surgery. The electrophysiologist read the IFU and a subsequent “Dear Doctor” letter elaborating the risk; he discussed fracture risk in general terms with the patient, obtained informed consent, and selected this lead primarily due to familiarity and procurement cost. No unique anatomical constraints drove the choice.\n\nEighteen months after implantation, the lead fractured, causing multiple inappropriate shocks and necessitating emergent extraction and re-implantation. The patient sues the manufacturer on a design-defect theory. Assume no federal preemption issues are raised in this case. The jurisdiction recognizes both (i) the consumer-expectation test (a product is defective if it is more dangerous than an ordinary consumer would expect when used as intended or reasonably foreseeable), and (ii) risk-utility balancing under the Restatement (Third) of Torts: Products Liability, which requires proof of a feasible alternative design that would have reduced foreseeable risks at reasonable cost without unduly compromising utility. The jurisdiction also follows the learned intermediary doctrine (manufacturers of prescription medical products discharge their duty to warn by adequately warning the prescribing physician, who acts as a learned intermediary).\n\nPlaintiff offers evidence that, at the time of sale, a feasible alternative design existed: a slightly thicker-insulation and conductor configuration that laboratory and clinical registry data suggested would reduce fracture incidence by about $70\\%$ (from $0.2\\%$ to approximately $0.06\\%$ over $3$ years) at an added manufacturing cost of $150$ per lead, with tradeoffs of a roughly $5\\%$ reduction in generator battery longevity and a small increase in lead stiffness that remained within accepted implantation parameters. Experts for both sides agree that both the original and alternative designs meet accepted clinical performance criteria, but disagree on whether the additional fracture risk in the original design is justified by its marginally smaller profile and marginally longer battery life.\n\nStarting from the core definitions of the consumer-expectation test, risk-utility balancing with a feasible alternative design, and the learned intermediary doctrine, and without assuming any special rules beyond those stated, which outcome is most likely under a careful application of these doctrines to the above facts?\n\nA. Under the consumer-expectation test, plaintiff likely prevails because ordinary patients expect zero fractures from life-sustaining implants; under risk-utility balancing, defendant likely prevails because the risk was inherent and unavoidable in a high-risk Class III device.\n\nB. Under the consumer-expectation test, defendant likely prevails because ordinary consumers lack specific safety expectations for complex ICD leads and any residual risk was framed by physician-mediated warnings; under risk-utility balancing, plaintiff likely prevails because a feasible alternative design with materially lower fracture risk and modest tradeoffs was available, making the original design not reasonably safe.\n\nC. Plaintiff likely prevails under both tests because a product failure that causes injury is itself evidence of a defective design in high-risk medical devices.\n\nD. Defendant likely prevails under both tests because the learned intermediary doctrine categorically bars product-defect claims when the physician was adequately warned, even if a safer alternative design existed.", "solution": "The problem statement will first be validated for scientific and logical soundness. Upon confirmation of its validity, a solution will be derived by rigorously applying the provided legal doctrines as formal principles to the given set of facts.\n\n### **Problem Validation**\n\n**Step 1: Extract Givens**\n\n- **Product:** Implantable Cardioverter-Defibrillator (ICD) lead.\n- **Regulatory Status:** FDA-approved via premarket approval (PMA).\n- **Design Feature:** Thin, high-fatigue-resistance conductor.\n- **Manufacturer's Warning (IFU  \"Dear Doctor\" letter):** An approximate conductor-fracture risk of $1$ in $500$ (which is $0.2\\%$) over the first $3$ years for patients with typical activity levels. The warning highlights that early detection is difficult and that fracture can lead to inappropriate shocks and revision surgery.\n- **Physician's Actions:** The electrophysiologist read the warnings, discussed general fracture risk with the patient, obtained informed consent, and selected the lead based on familiarity and procurement cost, not due to specific patient anatomy.\n- **Adverse Event:** The lead fractured $18$ months post-implantation, causing multiple inappropriate shocks and requiring emergent extraction and re-implantation.\n- **Legal Claim:** The patient sues the manufacturer on a design-defect theory.\n- **Legal Assumptions:** Federal preemption is not an issue.\n- **Applicable Legal Doctrines (Jurisdictional Rules):**\n    1.  **Consumer-Expectation Test:** A product is defective if it is more dangerous than an ordinary consumer would expect when used as intended or in a reasonably foreseeable manner.\n    2.  **Risk-Utility Balancing (Restatement (Third) of Torts: Products Liability):** Plaintiff must prove a feasible alternative design that would have reduced foreseeable risks at a reasonable cost, without unduly compromising the product's utility.\n    3.  **Learned Intermediary Doctrine:** A manufacturer of a prescription medical product discharges its duty to warn by providing an adequate warning to the prescribing physician.\n- **Evidence of Feasible Alternative Design (FAD):**\n    -   **Configuration:** Slightly thicker insulation and conductor.\n    -   **Risk Reduction:** Reduces fracture incidence by approximately $70\\%$ (from a $3$-year risk of $0.2\\%$ to approximately $0.06\\%$).\n    -   **Cost:** An added manufacturing cost of $\\$150$ per lead.\n    -   **Tradeoffs:** A roughly $5\\%$ reduction in generator battery longevity and a small increase in lead stiffness (which remains within accepted implantation parameters).\n- **Expert Opinions:** Experts agree both designs meet clinical performance criteria but disagree on whether the increased risk of the original design is justified by its marginal benefits (smaller profile, longer battery life).\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientific Grounding:** The scenario is scientifically and medically plausible. Conductor fracture is a known failure mode for ICD leads. The statistics, costs, and design tradeoffs (e.g., stiffness, battery life, diameter) are realistic parameters in medical device engineering. The problem is grounded in established principles of biomedical engineering and real-world medical device litigation. It is free from pseudoscience.\n- **Well-Posedness:** The problem is well-posed. It provides a set of facts and three explicitly defined legal \"rules\" or tests. The task is to apply these rules to the facts to determine the most logically consistent outcome. The question asks for the \"most likely\" outcome, acknowledging the probabilistic nature of legal analysis, which is appropriate. The problem is structured for a deductive analysis.\n- **Objectivity:** The language is objective and unbiased, presenting the facts, the legal framework, the plaintiff's evidence, and the points of expert disagreement without favoring one side.\n\n**Step 3: Verdict and Action**\n\nThe problem statement is valid. It is scientifically grounded, well-posed, objective, and self-contained. The analysis will proceed by applying the defined legal doctrines to the provided facts.\n\n### **Solution Derivation**\n\nThe analysis will proceed by systematically evaluating the plaintiff's design-defect claim under each of the two provided tests, and then considering the impact of the learned intermediary doctrine.\n\n**1. Analysis under the Consumer-Expectation Test**\n\nThe consumer-expectation test asks whether the product was \"more dangerous than an ordinary consumer would expect.\" For complex medical products like an ICD lead, the \"ordinary consumer\" (the patient) lacks the technical expertise to form specific expectations about failure rates or design parameters. Their expectations are almost entirely shaped by information conveyed by their physician. The problem states the physician \"discussed fracture risk in general terms with the patient\" before obtaining informed consent.\n\n-   **Plaintiff's Argument:** An ordinary person expects a life-sustaining device implanted in their heart to be highly reliable and not to fracture, especially within a relatively short period like $18$ months.\n-   **Defendant's Argument:** The ordinary consumer's expectation for such a complex device is not one of zero risk. It is an expectation conditioned by the warnings provided by their physician. Since the patient was warned of a \"fracture risk,\" the occurrence of that very risk cannot be, by definition, beyond their expectation. The actual risk of $0.2\\%$ over $3$ years (a success rate of $99.8\\%$) is high, and a layperson has no basis to expect it to be higher. Courts often find this test difficult to apply to prescription medical devices, siding with the defendant on the grounds that patient expectations are mediated by the physician.\n\n**Conclusion for Consumer-Expectation Test:** The defendant has the stronger argument. The existence of a physician-mediated warning about the specific type of failure that occurred makes it difficult for the plaintiff to prove the product was more dangerous than an ordinary, informed consumer would expect. Therefore, the defendant is likely to prevail under this test.\n\n**2. Analysis under Risk-Utility Balancing**\n\nThis test requires the plaintiff to prove a Feasible Alternative Design (FAD) existed that offers a better risk-utility profile. The analysis breaks down as follows:\n-   **Feasible Alternative Design (FAD):** The problem explicitly states that a FAD existed.\n-   **Reduced Foreseeable Risks:** The FAD would reduce the risk of conductor fracture, a serious failure, by a substantial margin ($70\\%$, from a rate of $0.2\\%$ to $0.06\\%$). This is a significant improvement in safety.\n-   **Reasonable Cost:** The added manufacturing cost is $\\$150$ per unit. In the context of a life-saving device with total implantation costs in the tens of thousands of dollars, this is a minor, and thus \"reasonable,\" cost increase.\n-   **Utility Compromise:** The tradeoffs are a small ($5\\%$) reduction in battery life and a minor increase in stiffness that \"remained within accepted implantation parameters.\" These compromises do not appear \"undue.\" A small decrease in battery life (leading to slightly more frequent replacement surgeries over many years) is arguably a very favorable tradeoff compared to a $70\\%$ reduction in the risk of sudden, catastrophic lead failure requiring emergent surgery.\n-   **Balancing:** The core of the test is balancing the risks and utilities of the chosen design against the FAD. The manufacturer's design offers marginally longer battery life and a smaller profile. The FAD offers a substantially lower risk of a known catastrophic failure mode for a minimal cost and with minor, clinically acceptable tradeoffs. A reasonable fact-finder would likely conclude that the safety gains of the FAD significantly outweigh its modest costs and tradeoffs. The original design, therefore, appears to be \"not reasonably safe\" when a superior alternative was available.\n\n**Conclusion for Risk-Utility Balancing:** The plaintiff has a strong case. All elements of the test appear to be met. The plaintiff is likely to prevail under this test.\n\n**3. Impact of the Learned Intermediary Doctrine**\n\nThe doctrine states that the manufacturer's **duty to warn** is discharged by adequately warning the physician. The facts confirm the manufacturer provided an adequate warning to the physician. However, this doctrine is a defense to a claim of **failure-to-warn**, not a claim of **design defect**. A manufacturer cannot excuse an unreasonably dangerous design simply by warning about its dangers, especially when a safer, feasible alternative exists. The warning is relevant to the risk-utility analysis (as it informs the physician's choice), but it does not act as a categorical bar to a design-defect claim.\n\n### **Option-by-Option Analysis**\n\n**A. Under the consumer-expectation test, plaintiff likely prevails because ordinary patients expect zero fractures from life-sustaining implants; under risk-utility balancing, defendant likely prevails because the risk was inherent and unavoidable in a high-risk Class III device.**\n-   This option's conclusion on the consumer-expectation test is weak; a \"zero fracture\" expectation is arguably an unreasonable standard for any complex device.\n-   This option's conclusion on risk-utility balancing is factually incorrect. The problem explicitly states that an alternative design existed, meaning the risk was *not* unavoidable.\n-   Verdict: **Incorrect**.\n\n**B. Under the consumer-expectation test, defendant likely prevails because ordinary consumers lack specific safety expectations for complex ICD leads and any residual risk was framed by physician-mediated warnings; under risk-utility balancing, plaintiff likely prevails because a feasible alternative design with materially lower fracture risk and modest tradeoffs was available, making the original design not reasonably safe.**\n-   This option's conclusion on the consumer-expectation test aligns perfectly with the analysis that the physician-mediated warning defeats the claim that the risk was unexpected.\n-   This option's conclusion on risk-utility balancing also aligns perfectly with the analysis that the plaintiff has strong evidence of a FAD with a superior risk-utility profile.\n-   Verdict: **Correct**.\n\n**C. Plaintiff likely prevails under both tests because a product failure that causes injury is itself evidence of a defective design in high-risk medical devices.**\n-   This premise is legally incorrect. The mere fact that a product failed and caused injury does not, in itself, prove a defect. The plaintiff must still satisfy the specific requirements of the recognized tests for defect (consumer expectation or risk-utility), which this option bypasses.\n-   Verdict: **Incorrect**.\n\n**D. Defendant likely prevails under both tests because the learned intermediary doctrine categorically bars product-defect claims when the physician was adequately warned, even if a safer alternative design existed.**\n-   This option incorrectly applies the learned intermediary doctrine. As analyzed above, this doctrine is a defense to failure-to-warn claims, not a categorical bar to design-defect claims. The existence of a safer alternative is the central issue in a risk-utility design-defect case, and a warning does not negate this.\n-   Verdict: **Incorrect**.", "answer": "$$\\boxed{B}$$", "id": "4496680"}, {"introduction": "The risk-utility test often requires a concrete comparison of design choices. This practice provides a hands-on, quantitative analysis of a foreseeable user-interface flaw in an infusion pump, a common source of medical error. You will weigh the effectiveness of a comprehensive redesign against merely strengthening warnings, demonstrating the legal principle that when a safer design is feasible, relying on warnings alone may not be enough to avoid liability. [@problem_id:4496725]", "problem": "A manufacturer supplies a general-floor Intravenous (IV) infusion pump cleared through United States Food and Drug Administration (FDA) section $510(k)$ premarket notification. The pump’s numeric entry interface uses a dual-field rate entry (digits to the left and right of a decimal) with a toggle to select milliliters per hour or milligrams per hour. Post-market surveillance and a hospital’s event reporting reveal a recurring pattern: nurses sometimes enter the intended rate into the wrong field or forget to confirm unit changes after scanning medications, leading to over-infusion or under-infusion. The manufacturer has two candidate risk controls in response to foreseeable user-interface errors: (i) a user-interface redesign (adding forced unit confirmation, removal of dual-field entry, and rate-range hard stops based on medication class), and (ii) strengthened warnings and instructions (bolded labeling, training module additions, and a required double-check protocol).\n\nAssume the following empirically supported parameters for a single device over its service life:\n- Baseline misprogramming error probability per infusion is $p_0 = 0.004$.\n- Conditional on a misprogramming error, the probability of a severe adverse event is $q_s = 0.10$ with average loss $H_s = \\$500{,}000$, and the probability of a minor adverse event is $q_m = 0.90$ with average loss $H_m = \\$2{,}000$.\n- Human factors validation shows the redesign reduces misprogramming errors by $70\\%$, yielding $p_r = p_0 \\times (1 - 0.70)$.\n- Strengthened warnings reduce misprogramming errors by $25\\%$ only when a double-check protocol is followed; observed compliance with the protocol is $c = 0.60$, yielding effective error probability $p_w = p_0 \\times \\left(1 - 0.25 \\times c\\right)$.\n- The pump performs $N = 30{,}000$ infusions over its life.\n- The per-device incremental cost for the redesign is $K = \\$400$. Label changes and training have negligible cost for the manufacturer compared to $K$.\n\nIn jurisdictions following Restatement (Third) of Torts: Products Liability, a product is defective in design when the foreseeable risks of harm could have been reduced or avoided by adoption of a reasonable alternative design and the omission of the alternative design renders the product not reasonably safe. The risk–utility test considers, among other factors, the magnitude of foreseeable harm, the probability of harm, and the feasibility and cost of a safer design. Under the learned intermediary doctrine, a prescription medical product manufacturer’s duty to warn runs to the healthcare professional rather than the patient, but this doctrine does not eliminate duties regarding reasonably safe design.\n\nWhich option best states the legally sound conclusion about whether warnings or redesign are the more effective risk controls and the implications for design defect liability?\n\nA. Because the learned intermediary doctrine shifts all responsibility to hospitals and nurses, adequate warnings and training eliminate any design defect; the manufacturer has no duty to change the user interface if professionals can be warned.\n\nB. The redesign is the superior and reasonable risk control under the risk–utility test: it provides substantially greater expected harm reduction than warnings at modest cost, and the learned intermediary doctrine does not excuse failure to adopt a feasible alternative design; the pump is defectively designed absent redesign.\n\nC. Federal preemption under Riegel v. Medtronic bars state-law design defect claims for devices cleared through section $510(k)$, so neither warnings nor redesign matters for liability.\n\nD. The consumer expectations test alone governs here; because nurses expect to double-check rates, strengthened warnings satisfy expectations, and redesign is unnecessary.\n\nE. Quantitative analysis shows strengthened warnings reduce expected harm more than the redesign, making warnings the preferred risk control and negating any design defect claim.", "solution": "Begin from foundational legal principles applicable to medical product design defect analysis. Under Restatement (Third) of Torts: Products Liability, a product is defective in design when foreseeable risks could have been reduced or avoided by adoption of a reasonable alternative design, and the omission renders the product not reasonably safe. The risk–utility test weighs the probability and magnitude of harm against the burden and feasibility of the alternative design. Warnings are a risk control but are generally subordinate to design changes when a feasible alternative design (FAD) can materially reduce the risk. The learned intermediary doctrine channels the duty to warn to healthcare professionals; it does not eliminate the duty to design reasonably safe products nor make warnings an absolute substitute for safer design.\n\nWe quantify expected harm to operationalize the risk–utility balancing. First, compute the expected loss per error:\n$$\nE_{\\ell} = q_s \\times H_s + q_m \\times H_m = 0.10 \\times \\$500{,}000 + 0.90 \\times \\$2{,}000 = \\$50{,}000 + \\$1{,}800 = \\$51{,}800.\n$$\nBaseline expected loss per infusion is:\n$$\nL_0 = p_0 \\times E_{\\ell} = 0.004 \\times \\$51{,}800 = \\$207.2.\n$$\nCompute the expected loss per infusion under redesign. The redesigned error probability is:\n$$\np_r = p_0 \\times (1 - 0.70) = 0.004 \\times 0.30 = 0.0012,\n$$\nso\n$$\nL_r = p_r \\times E_{\\ell} = 0.0012 \\times \\$51{,}800 = \\$62.16.\n$$\nCompute the expected loss per infusion under strengthened warnings with limited compliance. The effective error probability is:\n$$\np_w = p_0 \\times \\left(1 - 0.25 \\times c\\right) = 0.004 \\times \\left(1 - 0.25 \\times 0.60\\right) = 0.004 \\times 0.85 = 0.0034,\n$$\nso\n$$\nL_w = p_w \\times E_{\\ell} = 0.0034 \\times \\$51{,}800 = \\$176.12.\n$$\nNow, compute total life-cycle expected harm reductions over $N = 30{,}000$ infusions:\n\n- Redesign harm reduction per infusion:\n$$\n\\Delta L_r = L_0 - L_r = \\$207.2 - \\$62.16 = \\$145.04,\n$$\ntotal:\n$$\n\\Delta T_r = \\Delta L_r \\times N = \\$145.04 \\times 30{,}000 \\approx \\$4{,}351{,}200.\n$$\n\n- Warnings harm reduction per infusion:\n$$\n\\Delta L_w = L_0 - L_w = \\$207.2 - \\$176.12 = \\$31.08,\n$$\ntotal:\n$$\n\\Delta T_w = \\Delta L_w \\times N = \\$31.08 \\times 30{,}000 \\approx \\$932{,}400.\n$$\n\nCompare these reductions to the redesign’s per-device incremental cost $K = \\$400$. The redesign’s expected harm reduction (on the order of $\\$4.35 \\text{ million}$) is vastly greater than $K = \\$400$, indicating strong risk–utility support for adopting the redesign. Strengthened warnings provide substantially less expected benefit and depend on human compliance $c$, which is limited and variable; warnings are also vulnerable to the human factors causing the errors in the first place. Under Restatement (Third), when a feasible alternative design significantly reduces risk at modest cost, reliance on warnings alone is inadequate. The learned intermediary doctrine concerns to whom warnings must be given (healthcare professionals), but it does not absolve manufacturers from adopting a reasonable alternative design.\n\nAddress potential federal preemption. Under Riegel v. Medtronic, express preemption of state-law claims generally applies to devices with Premarket Approval (PMA). Devices cleared through section $510(k)$ premarket notification do not receive the same form of premarket approval, and design defect claims are not categorically preempted (see Medtronic, Inc. v. Lohr). Therefore, preemption does not bar the risk–utility analysis here.\n\nOption-by-option analysis:\n- A. This asserts that the learned intermediary doctrine shifts all responsibility to clinicians and that warnings suffice to eliminate any design defect duty. This misstates the doctrine; it allocates the duty to warn to healthcare professionals but does not eliminate the duty to design reasonably safe products. Given the substantial expected harm reduction from redesign at low cost, warnings alone are inadequate where a feasible alternative design exists. Verdict: Incorrect.\n\n- B. This states that the redesign is superior under risk–utility because it significantly reduces expected harm at modest cost and that the learned intermediary doctrine does not excuse failure to adopt a feasible alternative design, concluding the pump is defectively designed absent redesign. This aligns with the calculations ($\\Delta T_r \\gg \\Delta T_w$) and governing legal principles. Verdict: Correct.\n\n- C. This claims federal preemption bars state-law design defect claims for section $510(k)$ devices. That is generally incorrect; Riegel preemption is associated with PMA devices, and section $510(k)$ clearance does not categorically preempt design defect claims. Verdict: Incorrect.\n\n- D. This relies solely on the consumer expectations test and concludes warnings suffice because nurses expect to double-check. Modern analysis in Restatement (Third) emphasizes risk–utility and feasible alternative design for complex medical devices; consumer expectations alone are often inadequate. Quantitatively, warnings offer far less harm reduction than redesign. Verdict: Incorrect.\n\n- E. This asserts warnings reduce expected harm more than redesign. Our calculations show the opposite: $\\Delta T_r \\approx \\$4{,}351{,}200$ versus $\\Delta T_w \\approx \\$932{,}400$. Verdict: Incorrect.", "answer": "$$\\boxed{B}$$", "id": "4496725"}]}